0001193125-26-226702
SEC filingQ1 revenue declined 11.4% to $3.2M amid lower sales volume, driving a swing to operating loss of $318K despite gross margin expansion to 48.9% from cost savings and positive $98K free cash flow.
Revenue of $3.2 million in Q1 2026 decreased 11.4% from $3.6 million in the prior year quarter, primarily due to lower sales volume as noted in management's discussion. This topline weakness reflects ongoing pressures in the fragmented hemp market, where net product sales declined despite the company's focus on consumer products.
Gross profit of $1.6 million represented a milder 5.8% year-over-year decline from $1.7 million, with gross margin expanding to 48.9%. Management attributes this resilience to lower product costs, reduced losses, and additional cost savings initiatives. These improvements demonstrate effective supply chain discipline even as overall volumes softened, helping to cushion the revenue drop at the gross line.
Operating expenses showed progress through targeted reductions, particularly in general and administrative (G&A) costs. G&A decreased from the prior period due to lower legal and professional fees, insurance expense, depreciation, and other administrative reductions, though partially offset by higher stock-based compensation. Despite these efforts, operating income swung to a $318K loss from a slim $11K profit, as the revenue shortfall overwhelmed opex efficiencies. Operating margin stood at -10.0%, highlighting the need for topline recovery to restore profitability.
Net income deteriorated to a $643K loss from $109K, with diluted EPS remaining at $0.00. The wider shortfall stems from the operating loss combined with non-operating items, underscoring vulnerability to topline fluctuations.
Management has implemented strategic cost reductions, including employee headcount cuts, vendor spending controls, and delays in drug development expenses. However, the company anticipates near-term dependence on additional investment capital to fund operations and growth. The firm is also evaluating potential impacts from upcoming THC legislation effective November 2026 on its product portfolio, supply chain, and results. Efforts continue to boost revenue and operating cash flows to address liquidity needs.